Lord Abbett Micro Cap Growth C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Lord Abbett Micro Cap Growth Fund Class C LCMGX
- NAV / 1-Day Return 27.21 / −0.22 %
- Total Assets 198.5M
-
Adj. Expense Ratio
2.120%
- Expense Ratio 2.120%
- Distribution Fee Level Above Average
- Share Class Type Level Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 1,500
- Status Limited
- TTM Yield 0.00
- Turnover 107%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:11 AM GMT+0
Morningstar’s Analysis LCMGX
Will LCMGX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 23.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Cogent Biosciences Inc | 2.80 | 6M | Healthcare |
Forte Biosciences Inc Ordinary Shares | 2.70 | 6M | Healthcare |
Adaptive Biotechnologies Corp | 2.67 | 6M | Healthcare |
Aehr Test Systems | 2.65 | 6M | Technology |
Navan Inc Ordinary Shares - Class A | 2.59 | 5M | Technology |
Enliven Therapeutics Inc | 2.39 | 5M | Healthcare |
Lindblad Expeditions Holdings Inc | 2.16 | 5M | Consumer Cyclical |
CECO Environmental Corp | 2.03 | 4M | Industrials |
10x Genomics Inc Ordinary Shares - Class A | 2.02 | 4M | Healthcare |
Pattern Group Inc Ordinary Shares - Series A | 1.90 | 4M | Consumer Cyclical |